OmniAb Inc.

Stock Chart, Company Information, and Scan Results

$1.57(as of Sep 10, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

OmniAb Inc. Company Information, Fundamentals, and Technical Indicators

Stock Price$1.57
Ticker SymbolOABI
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees114
CountyUSA
Market Cap$226.0M
EBIDTA-51.3M
10-Day Moving Average1.60
P/E Ratio-2.62
20-Day Moving Average1.74
Forward P/E Ratio0.00
50-Day Moving Average1.89
Earnings per Share-0.61
200-Day Moving Average2.50
Profit Margin-407.36%
RSI38.28
Shares Outstanding144.0M
ATR0.11
52-Week High4.87
Volume377,550
52-Week Low1.22
Most Recent Support Level1.55
Book Value262.1M
Most Recent Resistance Level1.73
P/B Ratio0.64
Upper Keltner1.98
P/S Ratio7.24
Lower Keltner1.50
Debt-to-Equity Ratio1.98
Next Earnings DateUnknown
Cash Surplus5.6M
Next Ex-Dividend DateUnknown

OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company's animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. The company has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

OmniAb Inc. In Our Stock Scanner

As of Sep 11, 2025
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Triple BottomScan Type: Chart Pattern Scans
As of ---
example chart graphic
Scan Name: Double BottomScan Type: Chart Pattern Scans
As of ---
example chart graphic
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.